Abstract 2208P
Background
Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare form of non-small cell lung cancer which is frequently associated with EBV infection and displays high levels of immune cell infiltration. Immunotherapy, thus, is an attractive therapeutic strategy for the disease but the treatment response has been inconsistent, indicating a gap in our understanding of the tumor microenvironment (TME) of PLELC.
Methods
Imaging mass cytometry was used in this study to map the different cellular components and interactions in 33 PLELCs at different stages (19 early-stage, 6 medium-stage, and 8 advanced-stage).
Results
Component analysis showed differential B and Treg cell composition in the TME as cancer progresses. In spatial analyses, we discovered a convergent melting trend of immune cell distribution across different stages in the tumor and non-tumor regions (p<0.05). We also identified anti-tumor immunity markers assigned to specific cellular interactions (p<0.01). In the neighborhood analysis, we found that myeloid cells near the tumor may attenuate the ability of antigenic immune responses. Furthermore, we identified two spatial structures within the TME that could impact the infiltration of immune cells and the relapse of patients, and disease relapse in patients is associated with the level of immune cells inside the tumor region (p<0.01) and fibroblasts surrounding the tumor.
Conclusions
Our findings indicate that TME is heterogeneous and dynamic along the disease progression of PLELC such that cellular components, spatial interactions, and immune cell infiltration may play a significant role in disease recurrence. Moreover, profiling the TME may be helpful for understanding and selecting different immune treatments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2161P - Organization of hospital pharmaceutical consultations for cancer patients receiving oral anticancer drugs: A nationwide cross-sectional study
Presenter: Florian Slimano
Session: Poster session 07
2162P - Can artificial intelligence provide accurate and reliable answers to cancer patients' questions? Comparison of chatbots based on the ESMO Patient Guide about cancer pain
Presenter: Kadriye Bir Yucel
Session: Poster session 07
2163P - Supportive care in French community pharmacies: OncoPharma certification
Presenter: Jérôme Sicard
Session: Poster session 07
2164P - The impact of cancer patients’ face masks on oxygenation and Co2 retention during treatment
Presenter: Mert Sahin
Session: Poster session 07
2165P - A French overview of electronic patient-reported outcomes use in 2022
Presenter: Melina Hocine
Session: Poster session 07
2166P - Long-term consequences of SARS-CoV-2 infection in cancer patients
Presenter: Yana Debie
Session: Poster session 07
2167P - Are bone targeted agents (BTAs) still useful in times of immunotherapy? The SAKK 80/19 BTA study
Presenter: Michael Mark
Session: Poster session 07
2168P - At-home infusion of immunotherapy for patients with solid tumors: First results from a single-centre program
Presenter: Javier Marco Hernández
Session: Poster session 07
2169P - Immunotherapy-based treatment in elderly cancer patients: A real-world multicenter study
Presenter: Mengye He
Session: Poster session 07
2171P - Incidence of adverse events in patients treated with a combination of immune checkpoint blockers and chemotherapy: A real life cohort
Presenter: Layal Rached
Session: Poster session 07